Condition: Recurrent Endometrial Carcinoma · Recurrent Endometrial Clear Cell Adenocarcinoma · Recurrent Endometrial Endometrioid Adenocarcinoma · Sponsor: National Cancer Institute (NCI)
This phase Ib trial tests the safety, side effects, and best dose of M1774 when given with ZEN-3694 in treating patients with ovarian and endometrial cancer that has come back (recurrent). M1774 and ZEN-3694 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. M1774 and ZEN-3694 combined together has demonstrated to be better than either drug alone in killing ovarian tumor cells.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Augusta University Medical Center | Augusta, Georgia, United States | Suspended |
| University of Chicago Comprehensive Cancer Center | Chicago, Illinois, United States | Recruiting |
| University of Iowa/Holden Comprehensive Cancer Center | Iowa City, Iowa, United States | Recruiting |
| Wayne State University/Karmanos Cancer Institute | Detroit, Michigan, United States | Suspended |
| University of New Mexico Cancer Center | Albuquerque, New Mexico, United States | Recruiting |
| Case Western Reserve University | Cleveland, Ohio, United States | Active Not Recruiting |
| Cleveland Clinic Foundation | Cleveland, Ohio, United States | Recruiting |
| Ohio State University Comprehensive Cancer Center | Columbus, Ohio, United States | Recruiting |
| University of Oklahoma Health Sciences Center | Oklahoma City, Oklahoma, United States | Recruiting |
| NRG Oncology | Philadelphia, Pennsylvania, United States | Recruiting |
| University of Pennsylvania/Abramson Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
| Thomas Jefferson University Hospital | Philadelphia, Pennsylvania, United States | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05950464